Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
5.4
Journals
Marine Drugs
Special Issues
Metabolomic Study of Marine Streptomyces
share announcement

Metabolomic Study of Marine Streptomyces

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1811

Special Issue Editor

Dr. Um Soohyun

E-Mail Website
Guest Editor
College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Republic of Korea
Interests: natural products; marine drugs; cytotoxicity, antimicrobial agents; nonribosomal peptides; structure and activity; insect–microorganism symbiosis

Special Issue Information

Dear Colleagues,                

In recent years, the exploration of secondary metabolites produced by marine microorganisms, particularly streptomyces strains, has garnered significant attention within the scientific community. These versatile microorganisms have demonstrated immense potential in the synthesis of bioactive compounds with diverse applications. Streptomyces, known for their prolific secondary metabolite production, hold promise as sources of novel pharmaceutical agents, industrial enzymes, and biotechnological innovations. The scope of this Special Issue is multifaceted and delves into various aspects of the metabolomic study of marine streptomyces.

Dr. Um Soohyun
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine streptomyces
  • secondary metabolites
  • biosynthetic gene clusters
  • bioactive compounds
  • mechanisms of action
  • pharmaceutical applications
  • biotechnological potential
  • ecological significance

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2031 KiB  
Article
Multicopy Chromosome Integration and Deletion of Negative Global Regulators Significantly Increased the Heterologous Production of Aborycin in Streptomyces coelicolor
by Jia-Yi Li, Jun-Yu Liang, Zhao-Yuan Liu, Yue-Zhao Yi, Jing Zhao, Zhi-Yong Huang and Jun Chen
Mar. Drugs 2023, 21(10), 534; https://doi.org/10.3390/md21100534 - 13 Oct 2023
Cited by 1 | Viewed by 1613
Abstract
Aborycin is a type I lasso peptide with a stable interlocked structure, offering a favorable framework for drug development. The aborycin biosynthetic gene cluster gul from marine sponge-associated Streptomyces sp. HNS054 was cloned and integrated into the chromosome of S. coelicolor hosts with [...] Read more.
Aborycin is a type I lasso peptide with a stable interlocked structure, offering a favorable framework for drug development. The aborycin biosynthetic gene cluster gul from marine sponge-associated Streptomyces sp. HNS054 was cloned and integrated into the chromosome of S. coelicolor hosts with different copies. The three-copy gul-integration strain S. coelicolor M1346::3gul showed superior production compared to the one-copy or two-copy gul-integration strains, and the total titer reached approximately 10.4 mg/L, i.e., 2.1 times that of the native strain. Then, five regulatory genes, phoU (SCO4228), wblA (SCO3579), SCO1712, orrA (SCO3008) and gntR (SCO1678), which reportedly have negative effects on secondary metabolism, were further knocked out from the M1346::3gul genome by CRISPR/Cas9 technology. While the ΔSCO1712 mutant showed a significant decrease (4.6 mg/L) and the ΔphoU mutant showed no significant improvement (12.1 mg/L) in aborycin production, the ΔwblA, ΔorrA and ΔgntR mutations significantly improved the aborycin titers to approximately 23.6 mg/L, 56.3 mg/L and 48.2 mg/L, respectively, which were among the highest heterologous yields for lasso peptides in both Escherichia coli systems and Streptomyces systems. Thus, this study provides important clues for future studies on enhancing antibiotic production in Streptomyces systems. Full article
(This article belongs to the Special Issue Metabolomic Study of Marine Streptomyces)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop